LGD-3303
Aliases: LGD3303
Last verified: 2026-09-23
The short version
A SARM focused on bone/muscle with very low androgenic effects; never entered serious clinical development, but present on the gray market. Key fact: No controlled human trials exist. Everything known about LGD-3303 in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A SARM focused on bone/muscle with very low androgenic effects; never entered serious clinical development, but present on the gray market.
Mechanism of action
Selective AR agonism.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for LGD-3303. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Community: 10–20 mg/day. Dryness and strength without much water; rare experiences, the community treats it as a "specialized" SARM.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Dryness and strength without much water; rare experiences, the community treats it as a "specialized" SARM.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
10–20 mg oral daily.
- Cycle:
- 6–8 weeks.
- Break:
- 4+ weeks with SERM-based PCT.
Positioned as a 'dry' LGD — strength and hardness without the water retention associated with LGD-4033. Experiences are rare and the compound is treated as a specialized, second-tier option.
Human evidence
No controlled human trials exist. Everything known about LGD-3303 in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical (Ligand Pharmaceuticals).
Known risks
- Unknown in humans; suppression likely.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.